Navigation Links
Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
Date:2/24/2013

antihistamine. For the primary endpoint, the omalizumab 75 mg dose group did not demonstrate statistical significance compared to placebo. However, omalizumab 150 mg and 300 mg dose groups met the pre-specified primary endpoint and all eight pre-specified secondary endpoints in the ASTERIA II trial, except for the 150 mg dose that did not show a significant difference from placebo in the proportion of angioedema-free days from Week 4 to Week 12 of therapy. Patient response, as measured by the median time to Minimally Important Difference (MID) in itch severity score,  a secondary endpoint, occurred at Week 1 (300 mg dose) and Week 2 (150 mg dose), compared to Week 4 in the placebo group.

The incidence and severity of adverse events (AEs) was similar across treatment groups. The most frequently reported treatment-emergent adverse events in patients taking omalizumab (>10% in any omalizumab treatment arm) in the study (including treatment period and follow-up period) were nasopharyngitis (nasal and throat infection or common cold), idiopathic urticaria (hives and itching, trigger unknown) and headache.  Five (6.3%) patients experienced serious adverse events (SAEs) in the omalizumab 300 mg dose group, compared to two (2.5%) in the placebo group. In the 150 mg and 75 mg dose groups, one patient experienced SAEs in each group (1.1% and 1.3%, respectively). No deaths were reported during this study.

About Omalizumab
Omalizumab is not indicated for CIU.

Omalizumab is a biologic therapy unique in targeting immunoglobulin E (IgE). Research is ongoing to understand the mechanism of action of omalizumab in CIU and to investigate its potential impact on the drivers of CIU. Omalizumab is approved for the treatment of moderate to severe allergic asthma under the brand-name Xolair® in more than 90 countries, including the US since 2003 and the EU since 2005. In the US, Xolair is indicated for appropriate people who are
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Novartis Pharma Logistics, Inc. voluntarily recalling in Jamaica select lots of certain over-the-counter products due to bottle closure defect
2. Novartis Pharma Logistics, Inc. voluntarily recalling in Trinidad & Tobago select lots of certain over-the-counter products due to bottle closure defect
3. Novartis Pharma Logistics, Inc. voluntarily recalling in Curacao select lots of certain over-the-counter products due to bottle closure defect
4. Novartis Pharma Logistics, Inc. voluntarily recalling in Aruba select lots of certain over-the-counter products due to bottle closure defect
5. Novartis Pharma Logistics, Inc. voluntarily recalling in Barbados select lots of certain over-the-counter products due to bottle closure defect
6. Continued Uptake of Novartis/Incytes Jakafi Will Be the Greatest Driver of Growth in the Myelofibrosis Therapy Market
7. Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS
8. Thesan Pharmaceuticals offentliggør første runde af venturefinansieringen ledt af Novo Ventures og Novartis Venture Funds i fællesskab
9. Thesan Pharmaceuticals annuncia un finanziamento di serie A co-gestito da Novo Ventures e Novartis Venture Funds
10. Thesan Pharmaceuticals gibt Serie-A-Finanzierung unter gemeinsamer Führung von Novo Ventures und Novartis Venture Funds bekannt
11. Thesan Pharmaceuticals Announces Series A Funding Co-Led By Novo Ventures And Novartis Venture Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... MYERS, Fla. , Jan. 23, 2015  Today the ... of Novartis, Bexsero® for the prevention of serogroup ... 25. Bexsero and Pfizer,s vaccine Trumenba®, which received FDA ... helping prevent this devastating disease. "I ...
(Date:1/23/2015)... 23, 2015 A lot of discussion in the medical ... certain illnesses, injuries, or conditions. As medical science advances, doctors ... with ones that they consider to be more cutting edge. ... one textbook method of treatment that stands out as the ...
(Date:1/23/2015)... Jan. 23, 2015  The Partnership to Fight Chronic Disease (PFCD) released ... care leaders and a new study analyzing the impact of increased ... a nationwide coalition working to educate policy makers and the public ... Capitol was focused on how the Iowa ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2No One-Size-Fits-All Remedy for Hernia Correction 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3
... SAN FRANCISCO, Calif., May 10, 2011 Janssen ... Alzheimer,s Immunotherapy Program, Pfizer Inc., is pleased to ... health organization in Alzheimer,s care, support and research, ... Summits Climb for Alzheimer,s: Memories are Everything ...
... Vista Partners announced today that it ... (AMEX: HBP, TSX: HBP) ("the Company") with a twelve ... at Vista Partners stated, "The Company is developing products ... and most advanced, Interferon alpha-2b, is a potent immuno-modulatory ...
Cached Medicine Technology:Alzheimer's Association Salutes Advocate and Mountaineer Now Climbing Everest as Part of The 7 Summits Climb for Alzheimer's 2Alzheimer's Association Salutes Advocate and Mountaineer Now Climbing Everest as Part of The 7 Summits Climb for Alzheimer's 3Alzheimer's Association Salutes Advocate and Mountaineer Now Climbing Everest as Part of The 7 Summits Climb for Alzheimer's 4Vista Partners Initiates Coverage on Helix BioPharma Corporation; Target Price $6.20 2
(Date:1/22/2015)... City, Florida (PRWEB) January 22, 2015 IsoComforter, ... cold therapy machine with patented IsoTube design to treat specific ... has introduced the most progressive and easy to use patented ... treat post-operative and sports related orthopedic and muscle injuries. ...
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
(Date:1/22/2015)... 2015 As interest in the value of ... momentum worldwide, Rev. Eric J. Hall , president and ... (HCCN), will be the keynote speaker on January 27 at ... health system. , The conference, “Hope and Resilience: Innovative and ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a ... insurance policy . , Some types of vehicles cannot be ... newly released blog post to see if their vehicle qualifies for ... are some of the cars that cannot be covered by a ...
(Date:1/22/2015)... 22, 2015 Step into a macabre ... Science Museum of Virginia. Wicked Plants, the Museum’s latest ... unearths 75 poisonous, carnivorous and diabolical plants inside of ... to uncover the biochemical, physical and neurological processes between ...
Breaking Medicine News(10 mins):Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... “Hi, who’s on ... tone in her voice. A caller named Mary Ellen describes “very swollen legs from ... Maggie McDermott, RN, deadpans in her Irish brogue. “Now Magster, let’s not start right ... ...
... Key ... , ... 19, 2009 -- Key Metric Software has released Duplicate File Detective v3.0, a major ... a number of new features that focus on extending the scalability and ...
... minutes before intercourse significantly postponed orgasm, study finds , THURSDAY, ... first potential treatment for premature ejaculation has proved effective in ... , PSD502 -- which combines the drugs lidocaine and prilocaine ... intercourse. , The study of men in Canada, Poland and ...
... ... its 9th Annual Conference on Contemporary Pharmacovigilance and Risk Management Strategies from January 10-13, ... ... will host its 9th Annual Conference on Contemporary Pharmacovigilance and Risk Management ...
... MELVILLE, N.Y., Nov. 19 Long Island IVF, a full ... patients achieve successful pregnancies, is now offering a new program ... treatment. Through this program and a partnership with In Vitro ... amount of money couples pay for their comprehensive treatment plans ...
... Washington State Nurses Association (WSNA), representing more than 1,600 ... press conference today to highlight serious concerns about the safety ... this H1N1 pandemic. In response to numerous reports from ... hospital fully comply with CDC guidelines on H1N1 prevention and ...
Cached Medicine News:Health News:New National Nurse Talk Radio Show Takes Off with Humor, Health, and a Voice for the Patient Advocate 2Health News:New National Nurse Talk Radio Show Takes Off with Humor, Health, and a Voice for the Patient Advocate 3Health News:Duplicate File Detective v3.0 Provides Enterprise-Grade Duplicate File Management 2Health News:Spray May Delay Ejaculation 2Health News:DIA Safety Conference To Explore Solutions To Challenges Facing Pharmaocovigilance And Risk Management Strategies 2Health News:DIA Safety Conference To Explore Solutions To Challenges Facing Pharmaocovigilance And Risk Management Strategies 3Health News:Long Island IVF to Offer IVF Financial Share Program, Limiting Costs and Providing Refunds if IVF is Not Successful 2Health News:Respirators and H1N1 Information Distributed to Registered Nurses at Sacred Heart Medical Center Out of Concern for Nurse and Patient Safety 2Health News:Respirators and H1N1 Information Distributed to Registered Nurses at Sacred Heart Medical Center Out of Concern for Nurse and Patient Safety 3
... management software - was designed by ... improvement tool helps diabetes care providers ... bridges medicine with technology by providing ... information technology product. This diabetes ...
... making decisions about insulin dosages and other ... are guided by data from blood glucose ... the patterns that can be seen by ... the data is presented in organized and ...
... The Ex-PRESS ... that provides a simplified,method of ... open angle glaucoma.,Similar to trabeculectomy, ... pressure,by diverting the aqueous humor ...
... StabilEyes CTR is a device designed for ... during cataract removal surgery. It provides secondary ... compromised zonules. The CTR is a uniplanar, ... ultraviolet light absorbing polymethylmethacrylate (PMMA) with one ...
Medicine Products: